Wegovy's Early Lead To Narrow As Eli Lilly Prepares Foundayo Launch [Seeking Alpha]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Seeking Alpha
The approval follows Novo Nordisk A/S's (NVO) launch of an oral version of Wegovy in January. Orforglipron is projected to generate about $1.6 billion in revenue in 2026, compared with $11.4 billion for Wegovy, which itself is seen easing from roughly $12.4 billion in 2025 as competition intensifies. Love Employee/iStock via Getty Images Earlier this month, Eli Lilly and Co. ( LLY ) secured U.S. Food and Drug Administration approval for its once-daily obesity pill, orforglipron (brand name Foundayo), becoming only the second entrant in a nascent but potentially vast oral GLP-1 This article was written by Quick Insights Orforglipron is expected to overtake Wegovy by 2030, reaching $14.2 billion in revenue versus Wegovy's projected $12.3 billion. Diabetes treatments, especially Mounjaro ($7B) and Zepbound ($4B), are forecast to comprise 76% of sales, supporting consensus revenue of $17.4 billion and EPS of $6.77. LLY's metabolic franchise, anchored by Mounjaro, Zepbound
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Denecimig (Mim8) significantly reduced annualized bleeding rate in people with hemophilia A, regardless of inhibitor status, in phase 3 data published in NEJM [Yahoo! Finance]Yahoo! Finance
- Eli Lilly Slips as Canada Approves Generic Weight-Loss Drug [Yahoo! Finance]Yahoo! Finance
- Eli Lilly investors are eager for Foundayo insight after early launch data [Yahoo! Finance]Yahoo! Finance
- Eli Lilly investors are eager for Foundayo insight after early launch data [Yahoo! Finance Canada]Yahoo! Finance Canada
- Health Canada approves first generic version of Novo Nordisk's Ozempic [BNN Bloomberg (Canada)]BNN Bloomberg
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 4/27/26 - Form 6-K
- 4/20/26 - Form 6-K
- 4/20/26 - Form 6-K
- NVO's page on the SEC website